Northview Acquisition CORP

Profusa, Inc. has entered into an Option Agreement to acquire G3 Vision Labs, Inc. and its subsidiaries, a move that could significantly expand Profusa's presence in the diagnostics sector.

Profusa, Inc. has appointed Jack Stover as Executive Chairman and CEO, Ben Hwang as President, and Liviu Goldenberg as a director, alongside signing a non-binding term sheet to acquire a commercial-stage health diagnostics and toxicology testing company.

Profusa, Inc. has filed a Form 8-K announcing a 1-for-25 reverse stock split of its common stock, effective July 7, 2026, to reduce outstanding shares and adjust equity awards.

Profusa, Inc. has submitted an Advance Notice to Ascent Partners Fund LLC to purchase shares under their existing equity line of credit arrangement.

Profusa Inc. has amended its Asset Purchase Agreement with Bio Insights LLC, removing provisions for management stock issuance.

Profusa, Inc. has issued an Advance Notice to Ascent Partners Fund LLC to purchase common stock under an existing equity line of credit.

Profusa reports a $3.5 million net loss for Q1 2026 while navigating Nasdaq listing challenges and securing new capital.

Profusa, Inc. reported significant net losses and negative operating cash flows for Q3 2025, raising substantial doubt about its going concern ability while facing Nasdaq delisting notices and expanding its Bitcoin treasury strategy.

Profusa, Inc. (formerly NorthView Acquisition Corp.) reported a significant net loss and working capital deficit for Q2 2025, raising substantial doubt about its ability to continue as a going concern, despite completing its merger with Profusa, Inc. and securing new financing.

NorthView Acquisition Corp. reported a widened net loss and a substantial working capital deficit for Q1 2025, alongside its delisting from Nasdaq and ongoing efforts to finalize its business combination with Profusa by an extended June 2025 deadline.

NorthView Acquisition Corp. reports a net loss for the quarter ended September 30, 2024, while navigating a proposed merger with Profusa and ongoing Nasdaq listing compliance issues.

NorthView Acquisition Corp. reported a net loss of $397,487 for the second quarter of 2024, primarily due to operating costs and changes in the fair value of warrant liabilities, while continuing efforts to finalize a business combination with Profusa.

Profusa, Inc. filed its annual report detailing 2025 financial performance, ongoing product development for biosensors, and significant challenges including Nasdaq listing compliance.

NorthView Acquisition Corp.'s annual report reveals challenges including a Nasdaq delisting, a proposed merger with Profusa facing uncertainties, and substantial doubt about the company's ability to continue as a going concern.

NorthView Acquisition Corp.'s annual report on Form 10-K details the company's financials, merger agreement with Profusa, and ongoing efforts to complete a business combination.

Hrt Financial Lp reported changes in beneficial ownership of NorthView Acquisition Corp common stock on July 28, 2026.

Hrt Financial Lp reported changes in beneficial ownership of NorthView Acquisition Corp common stock on July 28, 2026.

Profusa, Inc. Director Jack E. Stover reports the conversion of a promissory note into a significant number of common shares.

CFO Fred Knechtel reported the conversion of a $1.87 million promissory note into 5.34 million shares of Profusa common stock.

Profusa's Chief Financial Officer, Fred S. Knechtel, received a substantial distribution of common stock and warrants from NorthView Sponsor I LLC.

NorthView Sponsor I, LLC distributed 4.74 million shares of Profusa common stock and 5.16 million warrants to its members for no consideration.

Profusa, Inc. is holding its 2026 Annual Meeting of Stockholders on June 23, 2026, to vote on several critical proposals including a reverse stock split, preferred stock issuance, and equity plan amendment.

Profusa, Inc. calls a special meeting to vote on a reverse stock split, auditor ratification, and meeting adjournment, primarily to regain Nasdaq listing compliance.

Profusa, Inc. has amended its bylaws to reduce the quorum requirement for stockholder meetings to 33 and 1/3% after its initial Special Meeting failed to achieve a quorum.

Profusa, Inc. is calling a Special Meeting of Stockholders to approve a significant convertible note financing and an increase in authorized common stock to support future growth and capital needs.

Profusa, Inc. is seeking stockholder approval for an Equity Line of Credit of up to $100 million with Ascent Partners Fund LLC, primarily to fund Bitcoin purchases.

A supermajority of stockholders and the board have approved an extension for the company to complete its initial business combination, pushing the deadline to August 22, 2025, and ratifying past corporate acts.

Profusa, Inc. has filed an amended registration statement to facilitate the resale of up to 179.3 million shares of common stock by selling stockholders.

Profusa, Inc. has filed a registration statement with the SEC to permit the resale of up to 179,272,293 shares of its common stock by selling stockholders.

Profusa, Inc. files an S-1/A detailing ongoing capital raises through an equity line and convertible notes, recent PPP loan forgiveness, a new Mayo Clinic license, and efforts to address Nasdaq listing deficiencies following a reverse stock split.

Profusa, Inc. filed an S-1/A to update accounting consent and correct offering expenses, while detailing significant capital raising activities through convertible notes and an equity line of credit.

Profusa, Inc. announces a best-efforts public offering of up to $45 million in units, pre-funded units, and warrants to fund operations and repay debt, while facing significant financial challenges and Nasdaq listing compliance issues.

Profusa, Inc. filed an S-1 registration statement for the resale of up to 42.6 million common shares, including those tied to a $100 million committed equity facility with Ascent Partners, and revealed a new treasury strategy to invest proceeds in Bitcoin.

Ascent Partners Fund LLC and affiliated entities report a 9.99% beneficial ownership in Profusa, Inc. common stock, including shares from convertible notes and a securities purchase agreement, subject to a beneficial ownership limitation.

A group of investors led by Ascent Partners and Eagle Claw Corp. has reported a 9.99% beneficial ownership stake in Profusa, Inc. following an internal management reorganization.

Ascent Partners Fund LLC and its affiliates have disclosed a 9.99% beneficial ownership stake in Profusa, Inc., primarily through convertible notes and a securities purchase agreement.

A group of investors, including Ascent Partners Fund LLC and individuals, has reported a 9.99% beneficial ownership stake in Profusa, Inc. through various convertible securities and purchase agreements.

A group of investors, including Ascent Partners Fund LLC and Dominion Capital LLC, has disclosed a 9.99% beneficial ownership stake in Profusa, Inc. common stock, primarily through a convertible promissory note.

Harraden Circle Investments and its affiliated entities have filed an amended Schedule 13G, indicating they are no longer beneficial owners of more than 5% of NorthView Acquisition Corp's Class A Common Stock.